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Abstract
Background: Ultra-high throughput sequencing technologies provide opportunities both for discovery of novel 
molecular species and for detailed comparisons of gene expression patterns. Small RNA populations are particularly 
well suited to this analysis, as many different small RNAs can be completely sequenced in a single instrument run.
Results: We prepared small RNA libraries from 29 tumour/normal pairs of human cervical tissue samples. Analysis of 
the resulting sequences (42 million in total) defined 64 new human microRNA (miRNA) genes. Both arms of the hairpin 
precursor were observed in twenty-three of the newly identified miRNA candidates. We tested several computational 
approaches for the analysis of class differences between high throughput sequencing datasets and describe a novel 
application of a log linear model that has provided the most effective analysis for this data. This method resulted in the 
identification of 67 miRNAs that were differentially-expressed between the tumour and normal samples at a false 
discovery rate less than 0.001.
Conclusions: This approach can potentially be applied to any kind of RNA sequencing data for analysing differential 
sequence representation between biological sample sets.
Background
Since the discovery that small RNA effectors define a
number of developmental transitions and biological
defence mechanisms [1,2], sequencing efforts in a variety
of organisms have led to the recognition of several dis-
tinct small RNA sub-classes. These small RNAs (~18-30
nucleotides in length) function by guiding sequence-spe-
cific gene silencing at the transcriptional and/or post-
transcriptional level and have been shown to play impor-
tant regulatory roles in diverse biological processes [3-5].
Among the small RNA classes, microRNA (miRNA) is
the most abundant class in mammals. Over the past 5
years, more than 8000 different miRNA genes have been
identified in animals and plants (miRBase release version
12.0 [6]), and the number is expected to continue grow-
ing.
miRNA genes were first discovered by forward genetic
methods. These methods led to the identification of sev-
eral miRNA genes associated with developmental pheno-
types in Caenorhabditis elegans (for example, lin-4, let-7
and lsy-6) [2,7-9] and programmed cell death in Droso-
phila melanogaster (for example, miR-14  and  bantam)
[10,11]. Forward genetics approaches are relatively ineffi-
cient for miRNA gene discovery, in part because of a
small mutagenic target size and in part due to functional
redundancy. The development of large-scale RNA
sequencing methods [12-15] has greatly facilitated
miRNA discovery, with thousands of miRNAs now iden-
tified from various cell lines and tissues from a variety of
organisms. Apart from serving as a tool for novel small
RNA discovery, the small RNA sequencing approach
offers the potential to quantify and detect variation in
mature miRNAs, including RNA editing [16-18] and 5'/
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3'-end variations [19-21]. Recent developments in ultra-
high throughput sequencing technology greatly augment
this approach, providing the possibility of a near-com-
plete view of miRNA profiles.
Small RNA profiling by deep sequencing has been
applied in an increasing variety of biological situations
(for example, [22-31]). While greatly expanding the possi-
bilities for precise expression profiling, sequencing-based
profiling methods also raise new quantitative issues in
recognizing and representing variation and significance
in the resulting data sets. Many parallel questions were
addressed in the early days of microarray analysis.
Although sequence count data is analogous in some ways
to microarray data, the two data types differ in numerous
ways. First, microarray data provides an analogue mea-
sure of sequence prevalence while sequencing is inher-
ently digital. Second, microarray analyses generally
operate above a low background level of non-specific and
off-target probe-array binding that can complicate the
analysis of low-abundance molecular species (particular
in cases where a related highly abundant product is pres-
ent). With large enough sample sets, sequence-based
analysis can avoid these background problems, allowing
exquisite sensitivity. Still, rare molecular species are cer-
tainly subject to stochastic fluctuations in sequence data
sets and these fluctuations can be large components of
the total signal in cases where the counts of individual
species are small. Microarray and sequence-counting
based approaches share certain challenges, including bio-
logical and non-biological contamination and sample
quality and reliability. Finally, it should be pointed out
that microarray and sequencing procedures each give rel-
ative (and not absolute) mea s u r e s  o f  s e q u e n c e  a b u n -
dance. Thus, the most informative comparisons look at
changes in an expression ratio (involving at least two
sequences) between two samples. This makes absolute
comparisons of RNA abundance for different sequences
problematic. Comparisons of relative RNA levels avoid
such challenges and have been the focus of many analyti-
cal processes in both areas. In this work, we generate and
analyse a large dataset of small RNA sequences in cervical
cancer/normal sample pairs. We show that this approach
provides an extensive coverage of miRNAs expressed in
human cervical cancer tissues and normal cervices,
including the detection of many previously known
human miRNAs and their respective miRNA* sequences,
as well as the identification of a number of novel miR-
NAs. Based on this sequence data we describe a statistical
approach for cancer classification and we propose a new
method for the identification of diagnostic miRNAs using
sequencing-based miRNA profiling data. This approach
should have general utility in analysing differential
sequence representation between biological sample sets.
Results
miRNA profiling by small RNA cDNA library sequencing
We captured, amplified and sequenced 58 small RNA
libraries prepared from 29 pairs of cervical cancer tissues
and matched normal tissues (Additional File 1). In addi-
tion, the capture, amplification and sequencing for two
small RNA libraries (G699N and G761T) were repeated
in order to determine the reproducibility of the results. A
total of 42,348,326 independent small RNA sequences
(25,007,613 from normal cervices and 17,340,713 from
cervical cancer samples) were obtained (Additional File
1). The average library coverage was 705,805 sequences
(ranging from 29,848 to 2,624,426 for individual libraries)
with the sequenced population containing 32.4%
(13,710,440) miRNA sequences representing 626 distinct
mature miRNAs (Additional File 2). Of these, 210 miRNA
genes produced sequencing reads corresponding to both
arms of the miRNA precursors. As expected, a majority
of miRNA genes displayed strand bias. The relative abun-
dance of most of the star forms (miRNA*) was lower than
that of their corresponding miRNAs. However, six miR-
NAs (miR-17, miR-202, miR-425, miR-493, miR-624 and
miR-625) had a higher number of sequencing reads origi-
nating from the annotated miRNA* strand than the
mature miRNA sequence across majority of the libraries
(Additional File 3). Some miRNA genes demonstrated a
nearly equal number of sequencing reads originating
from the 5' and 3' arms of the miRNA precursor.
The sequence data reveal a very broad range of expres-
sion levels for known miRNAs (based on sequence
counts): ~6% of miRNAs were detected at high sequence
counts (>104), 14% were in the intermediate range (103-
104), and the remaining were at low sequence counts
(<100) (Additional File 3).
Novel miRNA genes
To search for novel candidate miRNAs, we used criteria
as previously described [32]: (i) at least 20 consecutive
bases (measured from the start of the small RNA) aligned
to human genome without any gaps; (ii) formation of a
sufficiently low-energy (<-20 kcal/mol) secondary fold-
back hairpin structure with small internal bulge(s) within
the miRNA region and (iii) complete containment of the
cDNA sequence within one arm of a hairpin. The result-
ing set of hairpin-derived small RNAs was further analy-
sed to distinguish genuine miRNA precursors from other
RNAs with similar structures.
Sixty-four novel miRNA genes (88 distinct mature miR-
NAs) were identified from a total of 45,299 novel
sequence reads (Additional File 4). Twenty-three of these
newly identified miRNA candidates were represented
both in 5' and 3' arms of the hairpin precursor, providing
strong evidence for biogenesis from a hairpin precursor.
Two of the miRNA candidates were classified as mirtronsWitten et al. BMC Biology 2010, 8:58
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(intronic miRNA precursors that bypass Drosha process-
ing) [33-35]. A distinct characteristic of a mirtron is that
the miRNA precursor is directly adjacent to the splice
sites. Among the novel candidate miRNAs, we identified
eight putative antisense miRNAs (referring to those miR-
NAs derived from the antisense strand of annotated
miRNA genes). Seven of these are antisense to known
miRNA genes, while the eighth is antisense to a novel
miRNA identified in this study (miR-3622a  and  miR-
3622b). All new miRNAs (except one, miR-1323-3p) were
observed more than once and detected in more than one
library (Additional File 2). Although the majority of the
newly identified miRNAs was detected at low abundance
(as reflected by low sequence count across all the librar-
ies), some were rather prominent (Additional File 2).
Among these, miR-1246  was the most abundant with
>13,000 sequencing reads detected.
Forty-one of the new miRNAs were located in introns,
one in an exon, and five in the 5'/3' untranslated regions
of known genes; 17 were found in the intergenic regions.
Notably, miR-3608 is located adjacent to a vault RNA,
HVG-2 (Additional File 5). Vault RNAs are a noncoding
RNA family as part of the vault ribonucleoprotein com-
plex that has been suggested to be involved in multidrug
resistance [36]. Interestingly, this candidate was only
detected in cervical cancer samples (G547T, G659T and
G026T) (Additional File 2).
miRNA data analysis
Sequencing-based miRNA profiling does not provide
absolute measurements of miRNA expression, but rather
the relative counts of different miRNAs within each sam-
ple. As described in the previous section, miRNA-seq
data are typically characterized by variances in total
counts for each sample. These, as well as sequence counts
for individual miRNAs, will be subject to large sampling
noise. Moreover, in contrast to microarray data, the
miRNA-seq data involve non-negative counts.
All statistical analyses were performed on the cube-
rooted data, unless otherwise specified. The raw data had
a very skewed distribution, with many large values.
The cube-root transformation reduced this skewness
and gave the resultant data an approximate Poisson dis-
tribution, which was important for our log-linear model-
ling. The standard approach for testing differential
expression of genes measured on microarrays is to com-
pute a t-statistic for each gene; a permutation distribution
is then used to estimate false discovery rates. The use of a
t-statistic is justified if the data are approximately nor-
mally distributed with equal variances, as is the case for
microarray data after suitable transformations. However,
since sequencing data involve non-negative counts, the
assumption of normality is not appropriate. W e instead
develop a new method to identify differentially-expressed
sequences based on a Poisson log linear model.
In order to evaluate reproducibility between replicates,
we prepared two additional (duplicate) libraries for which
small RNA capture, amplification and sequencing were
carried out independently (and at a different time) from
the respective original samples. The two samples for
which this was done were G699N and G761T. From the
raw data, we saw correlations of 0.8966 between the two
libraries from G699N and 0.7836 for the two libraries
from G761T. For reference, the mean correlation between
pairs of different normal tissue samples was 0.6708, with
the mean correlation between pairs of samples from dif-
ferent tumours being 0.5735. The observed duplicates are
by no means perfectly concordant between replicate sam-
ples; in addition, we noted that some non-replicate pairs
show more correlation with each other than do the pairs
of replicates.
In order to visualize the 714-dimensional vectors of
miRNA expression in a lower-dimensional subspace, we
performed principal components analysis (PCA). The
principal components are the linear combinations of the
miRNAs that have the largest variance and provide infor-
mative axes for projection of the data. The analysis
revealed clear separation between tumour and normal
samples, but not between tumour types (Figure 1).
In order to assess the difference between normal and
tumour samples, we performed an unsupervised hierar-
chical clustering of the samples using complete linkage
and correlation-based distance. Hierarchical clustering
groups the samples by their similarity, in a bottom-up
fashion. As shown in Figure 2A, the clustering analysis
resulted in the identification of two major subgroups that
show an almost perfect separation between normal and
tumour samples. Recently, Berninger et al. also presented
a method for defining distances between samples for
miRNA expression profiling based on small RNA cloning
data [37]. For comparison, we also performed clustering
using the distance measure defined in Berninger et al.
and the results revealed two subgroups with good separa-
tion (Figure 2B).
In order to classify samples based on miRNA expres-
sion levels, we applied the nearest shrunken centroids
(NSC) method [38]. This method classifies samples by
computing an average miRNA expression vector for each
class; these average expression vectors are then shrunken
towards the overall miRNA expression mean across the
classes in order to avoid over-fitting and to obtain a clas-
sifier that makes use of only a subset of the miRNAs.
Cross-validation (CV), a process in which samples are
repeatedly split into training and test sets, was performed
in order to select the optimal number of miRNAs to use
in the classifier and to assess its accuracy. Applying NSC
for: (i) normal versus tumour resulted in 4/58 CV errorsWitten et al. BMC Biology 2010, 8:58
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(P  < 0.002); (ii) normal versus adenocarcinoma (ADC)
versus squamous cell carcinoma (SCC) resulted in 7/56
CV errors (P < 0.002); and (iii) ADC versus SCC resulted
in 4/27 CV errors (P = 0.064). The two adenosquamous
carcinoma (ASC) samples were excluded from analyses
(ii) and (iii). The miRNAs used in the three NSC classifi-
ers are shown in Additional Files 6, 7, 8.
In order to further explore the performance of NSC for
normal versus tumour samples, we randomly split the
samples into a training set of 40 samples and a test set of
18 samples. We trained NSC on the training set and
tested on the test set; this was repeated 100 times. This
resulted in an average of 1.77 errors for normal versus
tumour classification. The samples that were most fre-
quently misclassified were G529N, G696T, G701T,
G850N and G871T. Not surprisingly, the samples are
located near the boundary of the tumour and normal
Figure 1 Distinctive patterns of miRNA expression between cervical cancer and normal samples revealed by principal component analysis. 
microRNA incidence values from each sample were projected onto the first two principal components, using cube-rooted data. This two-dimensional 
representation of the ~714 dimensional primary data resulted in evident separation between normal and tumour samples but not between adeno-
carcinoma (ADC) and squamous cell carcinoma (SCC) samples. The first principal component explains 21.2% of the variation present in the data and 
the second explains 11.6%. ASC, adenosquamous cell carcinoma; T, tumour; N, normal.
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Figure 2 Clustering analyses of normal and tumour samples based on microRNA expression. (a) Samples were clustered using cube-rooted 
data and correlation-based distance (as described in Additional File 9). Two large subgroups and one small outgroup resulted, with separations 
1N:1T, 29N:1T and 0N:28T, respectively. The small outgroup consisted of tumour and normal samples from patient G428. The remaining samples were 
partitioned among the two larger subgroups, one of which consisted of the other 29 normal samples and one tumour sample, and the other consisted 
of the remaining 28 tumour samples. (b) Samples were clustered using the distance metric defined in Section 4.1 of Berninger et al. [37]. Again, an 
outgroup and two major subgroups resulted, with separations 0N:2T, 25N:2T and 5N:26T, respectively. For both panels, 'N' indicates a normal sample 
and 'T' indicates a tumour sample. Note: the duplicates of G699N and G761T are clustered near each other in both methods.
(a)
(b)Witten et al. BMC Biology 2010, 8:58
http://www.biomedcentral.com/1741-7007/8/58
Page 6 of 14
samples in the principal component analysis (PCA) plot
(Figure 1).
In order to identify miRNAs that are differentially
expressed between tumour and normal tissue, we needed
to address the fact that the data were characterized by a
high variance in sequence counts between samples as
well as between miRNAs, and the fact that the data were
discrete. For this purpose, we propose the use of a Pois-
son log-linear model. In this model, the cube-rooted
counts for each miRNA for each sample are taken as Pois-
son random variables and the logs of the means of these
Poisson variables are estimated using a linear model (see
Additional File 9). We allow a separate term for each
miRNA (since different miRNAs have different frequen-
cies) and for each sample (since some samples have much
higher counts of all miRNAs). An additional term for
each miRNA quantifies the extent to which each miRNA's
counts differ between tumour and normal tissue. That is,
we model 1 + Xij ~ Poisson(μij), where X denotes the cube-
rooted data matrix, iindexes the miRNAs, j indexes the
samples, and log(μij) = βi + γj + ρi(1jεTumour -1jεNormal). Here,
we are using indicator variable notation: 1A equals 1 if A
is true and 0 otherwise. In order to test how well the
model fits the data, we binned the observations based on
their fitted mean value in the Poisson model and esti-
mated the mean and variance of the observations in each
bin. As expected, under the Poisson model, the mean and
variance of the observations within each bin are approxi-
mately equal (Additional File 9). In our model,   can
be thought of as a score for the extent to which miRNA i
is differentially expressed between tumour and normal
samples. Here, the denominator se (ρi) indicates the stan-
dard error of ρi. In order to estimate the false discovery
rates (FDRs) for these scores, we randomly permuted
tumour and normal sample labels and compared the
observed   scores to the null distribution of these
scores obtained by permutations. For comparisons, we
also computed FDRs resulting from the log-linear model
on raw data, t-statistics on raw data, and t-statistics on
cube-rooted data. We found that our log-linear model on
cube-rooted data resulted in extremely low FDRs (Figure
3). Based on the permutation results, only ~4 of the 200
miRNAs with highest estimated absolute   are false
positives. The miRNAs with highest absolute 
scores are shown in Table 1. (A list of all miRNAs with
estimated absolute   scores and FDRs is available in
Additional File 10). All computations were carried out
using the R statistical package version 2.6.2.
Dependence of analysis on sequencing scale
Variation in overall sequence depth for different samples
will be present in any analysis of independent biological
specimens due to differences in tissue makeup and abun-
dance, with some additional variation due to technical
aspects of library construction and sequencing. Our dis-
cussions above make use of datasets with numbers of
sequence reads for the different samples that range from
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Table 1: miRNAs with significant changes determined by our Poisson log-linear model
miRNA
†
FDR§
miR-205 10.8525 0
miR-143 -8.292 0
miR-10b* -7.6723 0
miR-31 6.7684 0
miR-203 6.4009 0
miR-145* -6.2416 0
miR-944 6.1095 0
miR-1 -5.9363 0
miR-1246 5.7935 0
miR-204 -5.7914 0
miR-1303-3p 5.7469 0
miR-31* -5.6673 0
miR-126* -5.6346 0
miR-7 5.4282 0
miR-10b -5.3186 0
miR-425 5.2653 0
miR-200a* 5.1818 0
miR-125b -5.1426 0
miR-140-5p -5.0996 0
miR-21* 5.0897 0
miR-126 -5.0092 0
miR-183* 4.9398 0
miR-147b 4.9109 0
r
r
i
se i ()Witten et al. BMC Biology 2010, 8:58
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tens-of-thousands to over a million (Additional File 1). In
order to characterize the effect of sequencing scale on the
statistical results obtained, we generated resampled data
sets with various numbers of miRNAs. That is, for n =
103,104,105 and 106, we sampled with replacement n miR-
NAs from each of the 58 samples. We fit an NSC classifier
in order to distinguish between normal and tumour sam-
ples using the resampled data sets. Regardless of the value
of  n in this range, around 4/58 cross-validation errors
resulted. This suggests that the extent of library coverage
does not greatly affect the classifier. We also computed
the number of miRNAs found to be differentially-
expressed at a given FDR threshold for each of the resam-
pled data sets. The results can be seen in Additional File
11. As n increases, so does the number of miRNAs (as
expected, particularly with a stringent FDR threshold). As
n becomes quite large, the benefit of further increasing n
in terms of new miRNA identification becomes marginal.
These results indicate that conclusions can be drawn at
a variety of experimental scales, with deeper library cov-
erage resulting in more power for some statistical analy-
ses but with biological factors (for example, number and
uniformity of specimens) eventually exerting the major
limitations on interpretation as sequencing depth
increases.
Analysis of clustered miRNA expression
We defined a miRNA cluster as a set of miRNAs located
(i) within a 1 kb region or (ii) in close proximity (<4 kb),
with the same orientation and not separated by a miRNA
in the opposite orientation. Our data contained 56
miRNA clusters consisting of 236 miRNAs (Additional
File 12). In order to determine whether the clustered
miRNAs showed significant co-expression, we calculated
the average correlation of miRNA pairs within each clus-
t e r .  A s  s h o w n  i n  A d d i t i o n a l  F i l e  1 2 ,  w e  o b s e rv e d  t h a t
many clusters contain miRNAs that have more correlated
expression than one would expect due to chance. Twenty-
three miRNA clusters show significantly correlated
expression (P < 0.05). Of these, eight clusters are highly
correlated (P  < 0.001). These include miR-200b~429,
miR-34b~34c, miR-503~424, miR-29c~29b, miR-15b~16,
miR-200c~141, miR-99b~125a and  miR-25~106b  clus-
ters.
In order to determine whether any of the 56 clusters
contain miRNAs that are significantly associated with the
cervical cancer versus normal class labels, we applied the
log linear model and calculated the median scores for the
expressed miRNAs in each cluster. We found that 30 clus-
ters contain expressed miRNAs that are significantly
associated with the disease (P < 0.05; Additional File 13).
Seventeen of the 30 clusters are associated with increased
expression in cervical cancer and the remaining 13 clus-
ters are associated with reduced expression in cancer.
Interestingly, the two clusters that are most associated
with the cervical cancer versus normal class labels both
belong to the miR-200 family.
miR-155 4.7346 0
miR-25* 4.6551 0
miR-450a -4.584 0
miR-142-3p 4.5778 0
miR-99b -4.427 0
miR-424 -4.3806 0
miR-141* 4.3352 0.0001
miR-96 4.3028 0.0001
miR-3614-5p 4.2005 0.0001
† can be considered as a score for whether microRNA i is differentially expressed between tumour and normal: a large positive value indicates 
higher expression in tumour than normal.
§ Only microRNAs with low FDR (≤ 0.0001) are shown.
FDR = false discovery rate.
Table 1: miRNAs with significant changes determined by our Poisson log-linear model (Continued)Witten et al. BMC Biology 2010, 8:58
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Assessment of miRNA expression patterns
We compared the expression level of miR-21 and miR-
143 in all cervical cancer samples and matched normal
cervices used in this deep sequencing experiment with
previously published Northern blot results of the same
materials [32]. As shown in Additional File 14, both miR-
21 and miR-143 expression patterns obtained from the
sequencing data correlate well with the Northern data.
Modest differences, observed for a number of the sam-
ples, could be indicative of non-linearity in either assay;
alternatively such differences may be due to RNA cross-
hybridization (an ability to pick up alternate miRNAs
with the same probe), uncertainty in loading controls (in
some cases the ribosomal bands are difficult to quantitate
due to low levels) and to gel exposure artifacts (some
Northern bands are difficult to distinguish from optical
noise on the filters.).
Discussion
I n  t h i s  w o r k ,  w e  u s e d  h i g h  t h r o u g h p u t  s e q u e n c i n g
approaches combined with statistical analysis in order to
comprehensively characterize miRNA expression profiles
of 29 matched pairs of human cervical cancer and normal
cervical samples. Our results reveal a large number of
miRNAs detected in all libraries and provide quantitative
measures for a broad range of miRNA expression levels.
miR* and antisense miR sequences
One aspect of miRNA diversity comes from the ability to
produce two distinct miRNAs (termed miR-X and miR-
X*) from a given hairpin precursor RNA. In this case, the
two RNAs are distinct products of the same initial pro-
cessing product (pre-RNA), one located 5' and one 3' on
this precursor. The standard nomenclature for miRNAs
assigns the asterisk to the less abundant of the two forms
found in the first identifying study. In this work, we
detected a large number of miR* sequences, as well as
mature miRNAs from both 5' and 3' arms of the hairpin
precursor. For six miRNAs, we detected a higher number
of miR* sequence than the annotated mature miRNA
sequence in a majority of the libraries. This may indicate
that both 5' and 3' arms of the pre-miRNA can be
expressed in specific tissues/cells and that they may have
a functional relevance. Consistent with such a dual role,
reversals of abundance between miR and miR* have been
observed in several recent miRNA transcriptome analy-
ses [20,25,39] and miR/miR* strand selection have also
been shown to be different among different Argonaute
complexes [40,41]. Furthermore, Okamura et al. recently
demonstrated that some miRNA* species can associate
with the RNA-induced silencing complex and have inhib-
itory function [42]. These findings suggest that there are
additional levels of complexity in miRNA processing
which remain to be determined.
Three recent studies demonstrate that sense and anti-
sense miRNAs can be generated by bidirectional tran-
scription of the Drosophila Hox miRNA locus miR-iab-4
[43-45]. Interestingly, these sense and antisense miRNAs
are expressed in non-overlapping spatial domains and
have different targets. This phenomenon is not restricted
to the Hox loci in flies. Many more sense-antisense
miRNA pairs have also been identified in flies and mam-
mals [44,45]. Here, we provide further evidence for the
existence of sense-antisense miRNA pairs in human tis-
sues. Although these antisense miRNAs are low in abun-
dance (<100 copies in all libraries), their low
concentration does not rule out their possible biological
relevance. Further investigations are warranted in order
to assess the biological significance of these sense-anti-
sense miRNA pairs for a complete understanding of the
complexity of gene regulation by miRNAs.
miRNA complexity
Given that our small RNA libraries were prepared from a
single tissue type (cervical tissues), we unexpectedly
found a large number of miRNAs (ranging from 156 to
555) in each library, with the number depending on the
depth of sequencing. The data suggest that many miR-
NAs may lack complete tissue specificity, instead show a
continuum of expression variability in different tissues/
cells and physiological/pathological states. Alternatively,
a small population of distinct cell types may be present in
the samples used for the analysis and contribute to the
low-level detection of large numbers of miRNAs. Data
with cell lines, which have more homogenous cell popula-
tions, are of relevance to this issue. Consistent with the
hypothesis of extensive diversity in a single cell type,
Friedländer et al. recently detected a total of 213 known
miRNAs in a single HeLa sample [46].
miRNA expression in cervical cancer and matched controls
We used two statistical techniques to develop an under-
standing of the differences in miRNA expression between
normal and tumour cervical tissue.
First, we used NSC [38], a method originally developed
for microarray data analysis, to construct a classifier that
performs cancer class prediction from sequencing-based
miRNA expression profiling. The method successfully
classified the normal and tumour samples in approxi-
mately 16 of 18 test samples. Second, in order to identify
miRNAs that are differentially expressed between
tumour and normal tissue, we developed a simple log lin-
ear model for data from ultra-high throughput sequenc-
ing. This model is analogous to using a t-statistic to
identify differentially expressed genes in the case of
microarray data. Unlike the t-statistic, it is appropriate in
cases where the observations take on discrete values and
where variation occurs between samples as well asWitten et al. BMC Biology 2010, 8:58
http://www.biomedcentral.com/1741-7007/8/58
Page 10 of 14
between genes or miRNAs. This model resulted in the
identification of a set of miRNAs that distinguish tumour
from normal samples, with low FDRs (≤ 0.0001; Table 1
and Additional File 10). The model can potentially be
applied to any kind of sequencing data that produce
count data. Software implementing this log linear model
will be made freely available.
In agreement with our [32] and other previous findings
[47,48] with smaller data sets, the expression of miR-143
was significantly lower in cervical tumours as compared
to their matched normal controls. Importantly, miR-143
has been shown to inhibit cell growth in HeLa cells [48],
supporting its critical role in cervical carcinogenesis.
Also, a suppressor role of miR-143 has also been impli-
cated in different tumour types [49-51].
Among the most abundant miRNAs in the cervical can-
cer tissues, miR-205  has the highest estimated 
score in the log linear model. Its increased expression has
also been observed in a variety of carcinomas, including
cervical cancer [48], endometrioid endometrial adeno-
carcinoma [52], ovarian cancer [53], bladder cancer [54],
head and neck squamous cell carcinoma [55] and non-
small cell lung cancer [56]. Very recently, Yu et al. demon-
strated that the lipid phosphatase SHIP2 (SH-2 contain-
ing inositol 5'-phosphatase 2) can serve as a target of
miR-205 in SCC cells [57], with down-regulation of miR-
205 in SCC cells leading to a marked increase in apopto-
sis and cell death [57]. This will certainly provide an
important lead in investigating roles for miR-205 in cervi-
cal cancer.
An additional miRNA demonstrating strong regulation,
miR-944 (identified from small numbers of sequences in
an earlier study; [32]), was significantly more abundant in
the cervical cancer tissues than in their normal counter-
parts. This miRNA seems to be cervical tissue specific in
that it had not been previously observed in other tissues
or cell types [20]. miR-944 is located in the intron of TP63
(a member of the p53 family) and maps to chromosome
3q27-28, a region frequently amplified in cervical carci-
nomas [58-60]. It will be of interest to test for potential
roles of miR-944 in cervical carcinogenesis and/or pro-
gression.
Clustered miRNA expression
An analysis of clustered miRNA expression revealed
strong positive correlations among the closely neighbour-
ing miRNAs, suggesting that these miRNAs may be con-
trolled by common regulatory factor(s). The data are in
consistent with several previous findings [61-63]. Inter-
estingly, we found that the miR-200 family of miRNAs
(miR-200a/b/c,  miR-141, and miR-429) was highly co-
expressed in cervical cancer. These miRNAs are located
at two different genomic loci: the miR-200b~429 cluster
is located on chromosome 1, and the miR-200c~141 clus-
ter is located on chromosome 12. The co-expression of
these miR-200 loci suggests that these miRNA clusters
might be co-regulated by common regulator(s) and func-
tion together. In line with such hypothesis, Bracken et al.
recently demonstrated that both miR-200b~429 and miR-
200c~141  clusters are encoded by single polycistronic
primary miRNA transcripts [64]. Furthermore, the E-
cadherin  transcriptional repressor ZEB1  was found to
directly suppress transcription of both clusters [64,65].
As the five miR-200 family members contain very similar
seed sequences, these miRNAs are likely to regulate some
common targets. In support, several independent studies
showed that two transcriptional repressors of E-cadherin,
ZEB1 and ZEB2, are the direct targets of the miR-200
family miRNAs [66-68]. Although the expression of miR-
200  clusters is reduced in mesenchymal and invasive
cells, its over-expression has also been observed in ovar-
ian [69] and cervical [70] cancers.
A unique small RNA downstream of the Vault transcript
Among the novel miRNAs discovered here, miR-3608 has
the unique feature of sitting immediately downstream of
vault RNA, HVG-2 (Additional File 5). Vault RNAs are
small non-coding RNAs produced by RNA polymerase
III [71]. The possibility that miR-3608 might be produced
from the HVG-2 promoter suggests a type of dicistronic
heterologous Pol III transcript similar to tRNA-miRNA
dicistronic transcripts that have been identified in the
mouse gammaherpesvirus 68 [72] and in the C19MC
cluster of the human genome [73].
Conclusions
Our approach illustrates the high value of ultra-high
throughput sequencing data for novel miRNA discovery
and quantitative analysis of miRNAs. The statistical
approach described in this study is broadly applicable to
the analysis of any RNA sequencing data.
Methods
Clinical samples
Twenty-nine pairs of snap-frozen cervical tumour and
matched normal tissue were obtained from the Gyneco-
logic Oncology Group Tissue Bank (PA, USA). Of these
29 cases with paired specimens, 21 patients had a diagno-
sis of SCC, six had ADC and two had an intermediate
diagnosis of adenosquamous cell carcinoma (ASC)
(Additional File 1). All matched normal cervical tissues
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were obtained from the same patients and had been his-
topathologically verified. This study was approved by the
Institutional Review Board of Stanford University.
Small RNA library construction and Solexa sequencing
Small RNA isolation was performed using mirVana
miRNA isolation kit (Applied Biosystems/Ambion, TX,
USA). The capture and amplification procedure was done
as previously described [32], with slight modifications.
Purified small RNAs were ligated to the 3'-adaptor
["Linker-1", IDT Inc., IA, USA] and 5' adaptor [5'-
ACGCTCTTCCGATCTv-3' (uppercase, DNA; v = bar-
codes with triple RNA molecules: aaa, ggg, ccc or uuu;
IDT Inc, IA, USA)] oligonucleotides. Products from the
second ligation were gel-purified and reverse transcribed
using the reverse transcription primer [5'-ATTGATG-
GTGCCTACAG-3']. cDNA was amplified with 16-20
polymerase chain reaction cycles, using a forward primer
5'-GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT
TCC CTA CAC GAC GCT CTT CCG ATC T-3' and a
reverse primer 5'-CAA GCA GAA GAC GGC ATA CGA
GCT CTT CCG ATC TAT TGA TGG TGC CTA CAG-
3', to produce sequencing libraries that were subjected to
Solexa/Illumina sequencing platform (Illumina 1G
Genome Analyzer, CA, USA). Details of small RNA
library preparation protocol are available upon request.
The sequencing data have been deposited at Gene
Expression Omnibus (accession No. GSE20592).
Sequencing analysis
Individual sequence reads were initially generated follow-
ing sequencing using the Solexa software pipeline (Illu-
mina Inc, CA, USA). Reads from each of the pooled
libraries were then separated based on their barcode
sequence and mapped against human genome using
ELAND (Solexa, Illumina Inc, CA, USA). Perfectly
aligned sequences with at least 20 consecutive bases were
analysed further. Aligned sequences were then further
analysed with BLAST (blastn, [74]) and BLAT in order to
exclude other known structural RNAs.
In order to identify sequence reads that match previ-
ously identified miRNAs, we aligned sequences against
miRNA data from miRBase release version 10.1 [6] using
B L A T  [ 7 5 ] .  m i R N A s  w i t h  v a r y i n g  3 '  t e r m i n a l  w e r e
grouped together for tag counts. In order to uncover
novel miRNA genes, we identified hairpin-like RNA
structures in a window of 80 bases around recovered
small RNA sequences using mfold (version 3.2 [76]). All
predicted hairpin-like precursors were analysed carefully
in order to distinguish genuine miRNA precursors from
other RNA classes that may contain similar RNA struc-
tures (for example, snoRNAs, vault RNAs and tRNA-
derived repeat elements).
Statistical analysis
All statistical analyses were performed using the statisti-
cal software language R (version 2.6.2), freely available at
http://cran.r-project.org/[77].
The miRNA count data are characterized by very large
variances in both the total counts for each miRNA and
the total counts for each sample. Total miRNA counts
ranged from 1 to 2,253,073 (with a mean of 19,189), and
total sample counts ranged from 1,322 to 1,227,057 (with
a mean of 236,227). Because the row and column totals of
the data matrix vary by many orders of magnitude, cube-
rooted miRNA counts were used for almost all statistical
analyses. Let X denote the matrix of cube-rooted data,
where the rows denote the miRNAs and the columns
denote the samples. In order to visualize the samples, we
performed PCA after standardizing each column of X to
have mean zero and standard deviation 1.
NSC [38] is a classification method intended for the
case where the number of samples is small relative to the
numbers of features or variables. A centroid (or mean
vector) is computed for each class; the centroids are then
'shrunken' towards the overall centroid for the full data
set. New observations are then classified to the shrunken
centroid to which they are nearest. Depending on the
amount of shrinkage performed, only a subset of the fea-
tures will differ between the shrunken centroids. The
number of features that differ between the shrunken cen-
troids is treated as a tuning parameter for the method,
and is selected by CV. NSC was performed using the R
library 'pamr' on the cube-rooted data, after scaling each
column of the cube-rooted data by the total for that col-
umn. NSC classifiers were constructed to distinguish
between the following sets of classes: (i) tumour versus
normal; (ii) tumour versus ADC versus SCC; and (iii)
ADC versus SCC. For each classifier, the tuning parame-
ter value (controlling the number of miRNAs used by the
classifier) was selected by 10-fold CV. In order to obtain a
P-value for each classifier, CV errors were computed on
the real data and on null data obtained by randomly per-
muting the class labels for the samples. The P-value is
given by the fraction of null data sets resulting in CV
errors less than, or equal to, the CV error of the real data
set. To further explore the performance of NSC for nor-
mal versus tumour, we randomly split the samples into a
training set of 40 samples and a test set of 18 samples. We
trained NSC on the training set and tested it on the test
set; this was repeated 100 times. Only the first replicate in
each pair was used in the NSC analysis.
We also took an unsupervised approach to assess the
difference between normal and tumour samples: we used
complete linkage and correlation-based distance to hier-
archically cluster the cube-rooted data using the R lan-
guage function 'hclust'. For comparison, we performedWitten et al. BMC Biology 2010, 8:58
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clustering using the distance metric defined in Berninger
et al. [37].
In order to identify miRNAs that were differentially
expressed between normal and tumour samples, we
developed a Poisson log-linear model. The model
assumes that 1 + Xij ~ Poisson(μij) and log(μij) = βi + γj +
ρi(1jεTumour - 1jεNormal); that is, βi is the miRNA-specific
term, γj is the sample-specific term and ρi is the difference
between tumour and normal for miRNA i. We fit this
model in two steps, using an offset. The quantity
can be considered as a 'score' for whether miRNA i is dif-
ferentially expressed between tumour and normal; a large
positive value indicates higher expression in tumour than
in normal. FDRs were estimated by permutations:
tumour and normal sample labels were randomly per-
muted, and the estimated distributions of   for real
and permuted data were compared. Details are given in
Additional File 9. For comparison, we also computed
FDRs resulting from our log-linear model using raw,
rather than cube-rooted data, as well as FDRs resulting
from computing a paired two-sample t-statistic for each
miRNA (using both raw and cube-rooted data). Note that
the first replicate from each pair of duplicate libraries was
arbitrarily chosen for fitting the log linear model.
Analysis of miRNA clusters
In this analysis, we considered any two miRNA precur-
sors on the same chromosome strand (i) within 1 kb or
(ii) within close proximity (<4 kb), but not separated by a
miRNA in the opposite orientation as the same miRNA
cluster. Using this cutoff, we identified 56 miRNA clus-
ters, which contain 236 miRNAs from our datasets
(Additional File 15).
In order to determine whether the miRNAs in cluster k
have correlated expression, we computed the average cor-
relation of miRNA pairs within the cluster. We estimated
a null distribution for this average correlation by ran-
domly sampling nk miRNAs from the full set of miRNAs
and computing the average correlation of the pairs within
this null cluster. The null distribution was used to esti-
mate P-values for the extent to which the miRNAs in a
single cluster are correlated with each other.
In order to determine whether the miRNAs in cluster k
were significantly associated with the tumour/normal
phenotype, we fitted the log linear model mentioned pre-
viously and computed the median of the resulting scores
for the miRNAs in cluster k. We also permuted the
tumour/normal labels repeatedly and each time re-fit the
log linear model and recorded the resulting median
miRNA score for cluster k. These median scores for the
pe rm u t ed da ta se rved as a  n ul l dis t ribu t ion,  wh ic h we
used to obtain a P-value for the extent to which each clus-
ter k's miRNAs are associated with tumour/normal.
Additional material
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